FDA Approval Insights: Ramucirumab/Erlotinib in EGFR+ Metastatic NSCLC

Season 3 Episode 18  ·  Jul 06, 2020, 05:23 PM
Headliner
Share
Subscribe

In our exclusive interview, Edgardo S. Santos, MD, discusses the data that led to the approval of ramucirumab in combination with erlotinib and shares his thoughts on its utility in the frontline setting.

Share
Subscribe
Next
Marvels in Medicine: Dr. Jordan on Undertaking an Unforeseen Career in Breast Cancer
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air